Cordis has announced the launch of the ExoSeal Vascular Closure Device. ExoSeal incorporates a number of new advances in technology and simplicity of design to provide precise and secure extravascular arterial closure. Cordis received CE marking approval for ExoSeal in May 2010. This new product was launched during EuroPCR, in Paris, France.
ExoSeal was shown in a recent clinical trial to have an excellent clinical safety profile during vascular procedures. The ‘ECLIPSE Trial’ recorded no adverse clinical events and achieved a level of safety comparable to manual compression while significantly reducing time to ambulation. The device has achieved this level of clinical safety by combining easy-to-use functionality with trusted bioabsorbable technology and precise extravascular closure.
The ExoSeal Vascular Closure Device incorporates key advancements including the use of the Polyglycolic Acid Plug, two visual indicators to moderate control of the device and lockout features to reduce the risk of complications. The device is designed for ease of use, reducing the number of components and deployment steps.
“From our experience in the ECLIPSE trial, we were impressed with the safety and the effectiveness of this new closure device. It is very easy to use and nothing is left inside the vessel to threaten arterial blood flow. An advantage compared to other devices is the procedural sheath does not need to be changed which helps promote patient comfort. The two visual indicators are important for positioning the bioabsorbable plug ,” explains Marcus Wiemer, primary investigator, Department of Cardiology, Heart and Diabetes Center North Rhine-Westphalia, Ruhr University Bochum, in Bad Oeynhausen, Germany.
